Turn Therapeutics Inc. — SEC Form D Filing

Turn Therapeutics Inc. filed an SEC Form D on August 26, 2026, reporting $1.65M raised in Biotechnology.

Form D filing details

Filing
SEC Form D
Filing date
August 26, 2026
Amount reported
$1.65M
Industry
Biotechnology
Website
https://turntherapeutics.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients with moderate-to-severe eczema rely on systemic biologics and oral therapies that affect the entire body, leading to safety and tolerability concerns that impact long-term adherence. This is driven by an inflammatory cascade starting with IL-36 signaling, which intensifies itch, inflammation, and barrier dysfunction.

Solution

Turn Therapeutics develops first-in-class topical therapies, like GX-03, which act locally within the skin using their proprietary PermaFusion® drug delivery platform. This approach prevents unnecessary immune activation and reduces the production of inflammatory cytokines like IL-36, IL-31, and IL-4 at the source, without systemic exposure or injections.

Why now

There is a growing demand for alternatives to systemic biologics and oral therapies for chronic inflammatory skin conditions, driven by concerns over side effects and adherence.

Verdict

This cleared because the prospect of a topical biologic alternative for a chronic condition with established systemic treatments offered a clear path to market share, not because it promised a disruptive breakthrough in therapeutic mechanism. Investors were implicitly betting on a differentiated delivery method capturing patient and physician preference due to reduced systemic side effects. The upside was limited by the inherent challenge of topical efficacy matching systemic potency, and the risk of new systemic therapies emerging with improved safety profiles.

Source: SEC EDGAR Form D filing